Novartis trial setback for del-desiran in myotonic dystrophy study
Novartis said a late-stage study of del-desiran in myotonic dystrophy did not meet a target on a key metric. The company reaffirmed its sales guidance through 2030.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.